A Phase 2 interventional study of RO7046015 and RO7046015 in Parkinson's Disease, sponsored by Hoffmann-La Roche. Active, not recruiting at 55 sites in 5 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,649 studies in Parkinson Disease with a site in United States — 304 open to participants now, 386 under way, 7 of them phase 3. Parkinson Disease · United States.
Among the 1,649 studies in Parkinson Disease with a site in United States, this one is the 103rd largest by enrollment of the 1,256 interventional ones that give a count, is one of 85 that started in 2017, is one of 234 in phase 2, reaches primary completion later than 4 of the 383 other live ones, and was the 772nd registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →304 of the 1,649 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 45–75
University of Minnesota · Sites in United States
Ages 18+
Hoffmann-La Roche · Sites in United States, China, Ireland and 2 more countries
Ages 40–85
Medical University of South Carolina · Sites in United States
Ages 50–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,649 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 226 · Phase 2 304 · Phase 3 145 · Phase 4 75
First in 1991; this study’s year is marked. 85 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 316 is above the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 36 across the 1,256 interventional studies, 78 across the 379 observational. Of the 1,140 that completed or were terminated, 435 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
470 of 1,649 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 5 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
138 of the studies in Parkinson Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06976268Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease | 2027-08 |
| NCT06098612Massachusetts General HospitalPET Imaging Evaluation of [11C]SY08 | 2026-11 |
| NCT06489483University of Texas Southwestern Medical CenterAction Regulation Behavioral | 2026-11 |
| NCT05558189Stanford UniversityVibrotactile Coordinated Reset for the Treatment of Post Surgery Refractory Parkinson's Disease Patients | 2026-11-21 |
| NCT06773962TrueBinding, Inc.A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease | 2026-11-28 |
Add all 138 to your calendar (.ics) → With an account.
Among the 1,649 studies in Parkinson Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline. The study will consist of three parts: a 52-week, double-blind, placebo-controlled treatment period (Part 1) after which eligible participants will continue into an all-participants-on-treatment blinded dose extension for an additional 52 weeks (Part 2). Participants who complete Part 2 (including the 12-week treatment-free follow up visit assessing long term safety and efficacy of RO7046015) will be offered participation in Part 3 open-label extension (all-participants-on-RO7046015-treatment) for an additional 520 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive RO7046015 at high dose level as intravenous (IV) infusion every 4 weeks (Q4W) up to 52 weeks in Part 1.
Drug: RO7046015
Participants will receive RO7046015 at low dose level as IV infusion Q4W up to 52 weeks in Part 1.
Drug: RO7046015
Participants will receive placebo as IV infusion Q4W up to 52 weeks in Part 1.
Drug: Placebo
Part 1 RO7046015 high dose group participants and placebo group participants randomized to high dose level will receive RO7046015 at high dose level as IV infusion Q4W for additional 52 weeks in Part 2.
Drug: RO7046015
Part 1 RO7046015 low dose group participants and placebo group participants randomized to low dose level will receive RO7046015 at low dose level as IV infusion Q4W for additional 52 weeks in Part 2.
Drug: RO7046015
All participants who complete Part 1 and Part 2 will receive monthly IV infusions of RO7046015.
Drug: RO7046015
RO7046015 will be administered at dose of 4500 milligrams (mg) for participants with body-weight greater than or equal to (\>/=) 65 kilograms (kg) or 3500 mg for participants with body-weight less than (\<) 65 kg.
Also known as: PRX002; prasinezumab
RO7046015 will be administered at dose of 1512 mg to all participants in the indicated arm.
Also known as: PRX002; prasinezumab
RO7046015 placebo will be administered to all participants in the indicated arm.
Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score (Sum of Parts I, II, and III) at Week 52
The MDS-UPDRS is a multimodal scale consisting of four parts. Part I assessed non-motor experiences of daily living and has 2 components (Range 0-52). Part IA contains 6 questions and are assessed by the examiner (Range 0-24). Part IB contains 7 questions on non-motor experiences of daily living which was completed by the participant (Range 0-28). Part II assessed motor experiences of daily living (Range 0-52). It contained 13 questions completed by the participant. Part III assessed the motor signs of Parkinson's Disease (PD) and was administered by the rater (Range 0-132). Part III contained 33 scores based on 18 items. For each question a numeric score is assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. The MDS-UPDRS Total Score equals the sum of Parts I,II, and III (Range: 0-236). A higher score indicated more severe symptoms of Parkinson's disease.
Time frame: From baseline to Week 52
Change From Baseline in the MDS-UPDRS Part IA, Part IB, Part I Total, Part II Total, Part III Total and Part III Subscores
The MDS-UPDRS is a multimodal scale consisting of four parts. Part I assessed non-motor experiences of daily living and has 2 components (Range 0-52). Part IA contains 6 questions and are assessed by the examiner (Range 0-24). Part IB contains 7 questions on non-motor experiences of daily living which was completed by the participant (Range 0-28). Part II assessed motor experiences of daily living (Range 0-52). It contained 13 questions completed by the participant. Part III assessed the motor signs of Parkinson's Disease (PD) and was administered by the rater (Range 0-132). Part III contained 33 scores based on 18 items. There are 4 subscores in Part III: Bradykinesia, Rigidity, Resting tremors and Axial symptoms. For each question a numeric score is assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I,II, and III (Range:0-236). A higher score indicated more severe symptoms of Parkinson's disease.
Time frame: From baseline to Week 52
Change From Baseline in Dopamine Transporter Imaging With Single Photon Emission Computed Tomography (DaT-SPECT) Striatal Binding Ratio (SBR) in the Putamen Ipsilateral to the Clinically Most Affected Side
DaT-SPECT (dopamine transporter imaging with single photon emission computed tomography) is a dopamine transporter SPECT imaging that uses a radioactive agent called 123\^I-ioflupane to quantify the density of the dopamine transporters in the striatum. Changes from baseline to week 52 in DaT-SPECT striatal binding ratios (SBRs; reference region: occipital cortex) in the putamen ipsilateral to the clinically most affected side were analyzed.
Time frame: From baseline to Week 52
Change From Baseline in Montreal Cognition Assessment (MoCA) Total Score
The Montreal Cognitive Assessment (MoCA) is a rapid screening that was developed to be more sensitive to participants presenting with mild cognitive complaints. It briefly assesses short term and working memory, visuospatial abilities, executive function, attention, concentration, language and orientation. Scores on the MoCA test range from 0-30. Higher scores are associated with better cognitive function.
Time frame: From baseline to Week 52
Change From Baseline in Clinical Global Impression of Improvement (CGI-I) Score
The CGI-I was intended as a measure of change in health status. CGI-I scores ranged from 1 (very much improved) through to 7 (very much worse). For the CGI-I, participants were divided into one of two groups, Responders or Progressors. Responders were scored on a scale of 1-4 which was rated as "no change", "minimally improved", "much improved" or "very much improved." Progressors were scored on a scale of 5-7 which was rated as "minimally worse", "much worse" or "very much worse." The percentage of participants rated by CGI-I Scale grouping at week 52 was analyzed using a logistic regression model.
Time frame: From baseline to Week 52
Change From Baseline in Patient Global Impression of Change (PGIC) Score
The PGIC was intended as a measure of change in health state from the participants perspective. PGIC scores ranged from 1 (very much improved) through to 7 (very much worse). For the PGIC, participants were divided into one of two groups, Responders or Progressors. Responders were scored on a scale of 1-4 which was rated as "no change", "minimally improved", "much improved" or "very much improved." Progressors were scored on a scale of 5-7 which was rated as "minimally worse", "much worse" or "very much worse." The percentage of participants rated by PGIC Scale grouping at week 52 was analyzed using a logistic regression model.
Time frame: From baseline to Week 52
Change From Baseline in Schwab and England Activity of Daily Living (SE-ADL) Score
The SE-ADL is a single item scale assessing Activities of Daily Living on a scale ranging from 0% (bedridden) to 100% (completely independent), using 10% intervals.
Time frame: From baseline to Week 52
Time to Worsening in Motor or Non-Motor Symptoms
This outcome measure is defined as the time to between first dose of study medication and the date when the particiapnt increases in MDS-UPDRS Part I (Range 0-52) of 3 or more points, or in MDS-UPDRS Part II (Range 0-52) of 3 or more points, whichever comes first. A higher score indicated more severe motor signs of Parkinson's disease.
Time frame: From baseline to Week 52
Time to Start of Dopaminergic Parkinson's Disease Treatment
This endpoint is defined as the time between first dose of study medication and the date when the participant starts dopaminergic treatment.
Time frame: From baseline to Week 52
Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was any AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: From baseline to Week 52
Percentage of Participants With Anti-Drug Antibodies (ADAs) Against RO7046015
Samples of the participant's blood was taken to evaluate anti-drug antibodies (ADA). The number of ADA positive participants, Treatment-induced and Treatment-enhanced was reported. Treatment-induced = participants with ADA negative or missing data at baseline but develop an ADA response following exposure to the study drug. Treatment-enhanced = participants with ADA positive at baseline and the titre of one or more post-baseline samples is at least \>=4 fold increase greater than the baseline titre sample.
Time frame: Baseline, Pre-dose (0 hours) on Weeks 4, 20, 36, 52, 56, 68, 80, and 104; at early termination (up to Week 104), and follow-up (12 weeks after last dose up to Week 116)
Systemic Clearance (CL) of RO7046015
Clearance is a measure of the rate at which a drug is removed from the body.
Time frame: Predose (0 hours) and end of infusion (infusion length=2 hours or less) on Baseline, Weeks 4, 20, 36, 52, 56, 68, 80, and 104; at Day 7, Day 14, early termination (up to Week 104), and follow-up (12 weeks after last dose up to Week 116)
Apparent Volume of Distribution (Vz/F) of RO7046015
Volume of distribution is defined as the theoretical volume which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
Time frame: Predose (0 hours) and end of infusion (infusion length=2 hours or less) on Baseline, Weeks 4, 20, 36, 52, 56, 68, 80, and 104; at Day 7, Day 14, early termination (up to Week 104), and follow-up (12 weeks after last dose up to Week 116)
Area Under the Serum Concentration-Time Curve (AUC) of RO7046015 Over the Dosing Interval
AUC is defined as the measure of RO7046015 plasma concentration over time.
Time frame: Baseline over the duration of the study
Maximum Observed Serum Concentration (Cmax) of RO7046015 at Steady-state
Cmax is the maximum observed plasma concentration of RO7046015.
Time frame: Baseline over the duration of the study
Minimum Observed Serum Concentration (Ctrough) of RO7046015 at Steady-state
Cmin is the minimum observed plasma concentration of RO7046015.
Time frame: Baseline over the duration of the study
Participants were enrolled at 57 sites in 5 different countries. 1 site had only 1 screen failure and no active participants were enrolled there.
| Milestone | Part 1: Placebo | Part 1: RO7046015 Low Dose | Part 1: RO7046015 High Dose |
|---|---|---|---|
| Started | 105 | 105 | 106 |
| Completed | 105 | 101 | 104 |
| Not completed | 0 | 4 | 2 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Participant moved out of country | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 3 | 1 |
The MDS-UPDRS is a multimodal scale consisting of four parts. Part I assessed non-motor experiences of daily living and has 2 components (Range 0-52). Part IA contains 6 questions and are assessed by the examiner (Range 0-24). Part IB contains 7 questions on non-motor experiences of daily living which was completed by the participant (Range 0-28). Part II assessed motor experiences of daily living (Range 0-52). It contained 13 questions completed by the participant. Part III assessed the motor signs of Parkinson's Disease (PD) and was administered by the rater (Range 0-132). Part III contained 33 scores based on 18 items. For each question a numeric score is assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. The MDS-UPDRS Total Score equals the sum of Parts I,II, and III (Range: 0-236). A higher score indicated more severe symptoms of Parkinson's disease.
| Units on a scale | Part 1: Placebo | Part 1: RO7046015 Low Dose | Part 1: RO7046015 High Dose |
|---|---|---|---|
| Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score (Sum of Parts I, II, and III) at Week 52 | 9.37 ± 1.221 | 7.35 ± 1.225 | 8.75 ± 1.234 |
The MDS-UPDRS is a multimodal scale consisting of four parts. Part I assessed non-motor experiences of daily living and has 2 components (Range 0-52). Part IA contains 6 questions and are assessed by the examiner (Range 0-24). Part IB contains 7 questions on non-motor experiences of daily living which was completed by the participant (Range 0-28). Part II assessed motor experiences of daily living (Range 0-52). It contained 13 questions completed by the participant. Part III assessed the motor signs of Parkinson's Disease (PD) and was administered by the rater (Range 0-132). Part III contained 33 scores based on 18 items. There are 4 subscores in Part III: Bradykinesia, Rigidity, Resting tremors and Axial symptoms. For each question a numeric score is assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I,II, and III (Range:0-236). A higher score indicated more severe symptoms of Parkinson's disease.
| Units on a scale | Part 1: Placebo | Part 1: RO7046015 Low Dose | Part 1: RO7046015 High Dose |
|---|---|---|---|
| Part IA | -0.19 ± 0.119 | -0.27 ± 0.119 | -0.10 ± 0.121 |
| Part IB | 0.94 ± 0.247 | 0.90 ± 0.248 | 0.96 ± 0.251 |
| Part I total | 0.77 ± 0.295 | 0.59 ± 0.297 | 0.89 ± 0.300 |
| Part II total | 2.75 ± 0.373 | 3.09 ± 0.375 | 2.69 ± 0.376 |
| Part III total | 5.57 ± 0.897 | 3.69 ± 0.900 | 4.55 ± 0.911 |
| Part III subscore - rigidity | 0.61 ± 0.263 | 0.70 ± 0.265 | 0.86 ± 0.268 |
| Part III subscore - bradykinesia | 2.79 ± 0.556 | 1.72 ± 0.560 | 2.35 ± 0.565 |
| Part III subscore - resting tremor | 1.20 ± 0.231 | 0.59 ± 0.233 | 0.79 ± 0.234 |
| Part III subscore - axial symptoms | 0.19 ± 0.077 | 0.11 ± 0.078 | 0.18 ± 0.079 |
DaT-SPECT (dopamine transporter imaging with single photon emission computed tomography) is a dopamine transporter SPECT imaging that uses a radioactive agent called 123\^I-ioflupane to quantify the density of the dopamine transporters in the striatum. Changes from baseline to week 52 in DaT-SPECT striatal binding ratios (SBRs; reference region: occipital cortex) in the putamen ipsilateral to the clinically most affected side were analyzed.
| Striatal Binding Ratio (SBR) | Part 1: Placebo | Part 1: RO7046015 Low Dose | Part 1: RO7046015 High Dose |
|---|---|---|---|
| Change From Baseline in Dopamine Transporter Imaging With Single Photon Emission Computed Tomography (DaT-SPECT) Striatal Binding Ratio (SBR) in the Putamen Ipsilateral to the Clinically Most Affected Side | -0.08 ± 0.018 | -0.10 ± 0.018 | -0.11 ± 0.018 |
The Montreal Cognitive Assessment (MoCA) is a rapid screening that was developed to be more sensitive to participants presenting with mild cognitive complaints. It briefly assesses short term and working memory, visuospatial abilities, executive function, attention, concentration, language and orientation. Scores on the MoCA test range from 0-30. Higher scores are associated with better cognitive function.
| Units on a scale | Part 1: Placebo | Part 1: RO7046015 Low Dose | Part 1: RO7046015 High Dose |
|---|---|---|---|
| Change From Baseline in Montreal Cognition Assessment (MoCA) Total Score | 0.07 ± 0.177 | 0.30 ± 0.181 | 0.51 ± 0.178 |
The CGI-I was intended as a measure of change in health status. CGI-I scores ranged from 1 (very much improved) through to 7 (very much worse). For the CGI-I, participants were divided into one of two groups, Responders or Progressors. Responders were scored on a scale of 1-4 which was rated as "no change", "minimally improved", "much improved" or "very much improved." Progressors were scored on a scale of 5-7 which was rated as "minimally worse", "much worse" or "very much worse." The percentage of participants rated by CGI-I Scale grouping at week 52 was analyzed using a logistic regression model.
| Percentage of participants | Part 1: Placebo | Part 1: RO7046015 Low Dose | Part 1: RO7046015 High Dose |
|---|---|---|---|
| Progressors | 56.6 | 50.0 | 48.6 |
| Responders | 43.4 | 50.0 | 51.4 |
The PGIC was intended as a measure of change in health state from the participants perspective. PGIC scores ranged from 1 (very much improved) through to 7 (very much worse). For the PGIC, participants were divided into one of two groups, Responders or Progressors. Responders were scored on a scale of 1-4 which was rated as "no change", "minimally improved", "much improved" or "very much improved." Progressors were scored on a scale of 5-7 which was rated as "minimally worse", "much worse" or "very much worse." The percentage of participants rated by PGIC Scale grouping at week 52 was analyzed using a logistic regression model.
| Percentage of participants | Part 1: Placebo | Part 1: RO7046015 Low Dose | Part 1: RO7046015 High Dose |
|---|---|---|---|
| Progressors | 58.1 | 50.7 | 53.5 |
| Responders | 41.9 | 49.3 | 46.5 |
The SE-ADL is a single item scale assessing Activities of Daily Living on a scale ranging from 0% (bedridden) to 100% (completely independent), using 10% intervals.
| Units on a scale | Part 1: Placebo | Part 1: RO7046015 Low Dose | Part 1: RO7046015 High Dose |
|---|---|---|---|
| Change From Baseline in Schwab and England Activity of Daily Living (SE-ADL) Score | -1.83 ± 0.644 | -2.56 ± 0.650 | -2.50 ± 0.647 |
This outcome measure is defined as the time to between first dose of study medication and the date when the particiapnt increases in MDS-UPDRS Part I (Range 0-52) of 3 or more points, or in MDS-UPDRS Part II (Range 0-52) of 3 or more points, whichever comes first. A higher score indicated more severe motor signs of Parkinson's disease.
| Days | Part 1: Placebo | Part 1: RO7046015 Low Dose | Part 1: RO7046015 High Dose |
|---|---|---|---|
| Time to Worsening in Motor or Non-Motor Symptoms | 174.0 (168.0 to 225.0) | 169.0 (117.0 to 173.0) | 170.0 (168.0 to 222.0) |
This endpoint is defined as the time between first dose of study medication and the date when the participant starts dopaminergic treatment.
| Days | Part 1: Placebo | Part 1: RO7046015 Low Dose | Part 1: RO7046015 High Dose |
|---|---|---|---|
| Time to Start of Dopaminergic Parkinson's Disease Treatment | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was any AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| Percentage of participants | Part 1: Placebo | Part 1: RO7046015 Low Dose | Part 1: RO7046015 High Dose |
|---|---|---|---|
| AEs | 82.9 | 93.3 | 91.5 |
| SAEs | 4.8 | 6.7 | 7.5 |
Samples of the participant's blood was taken to evaluate anti-drug antibodies (ADA). The number of ADA positive participants, Treatment-induced and Treatment-enhanced was reported. Treatment-induced = participants with ADA negative or missing data at baseline but develop an ADA response following exposure to the study drug. Treatment-enhanced = participants with ADA positive at baseline and the titre of one or more post-baseline samples is at least \>=4 fold increase greater than the baseline titre sample.
Results for this outcome have not been posted.
Clearance is a measure of the rate at which a drug is removed from the body.
Results for this outcome have not been posted.
Volume of distribution is defined as the theoretical volume which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
Results for this outcome have not been posted.
AUC is defined as the measure of RO7046015 plasma concentration over time.
Results for this outcome have not been posted.
Cmax is the maximum observed plasma concentration of RO7046015.
Results for this outcome have not been posted.
Cmin is the minimum observed plasma concentration of RO7046015.
Results for this outcome have not been posted.
Collected over Baseline up to Week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Placebo | 0/105 (0%) | 5/105 (4.8%) | 57/105 (54.3%) |
| Part 1: RO7046015 Low Dose | 0/105 (0%) | 7/105 (6.7%) | 67/105 (63.8%) |
| Part 1: RO7046015 High Dose | 0/106 (0%) | 8/106 (7.5%) | 69/106 (65.1%) |
| Event | Part 1: Placebo | Part 1: RO7046015 Low Dose | Part 1: RO7046015 High Dose |
|---|---|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 0/105 | 0/105 | 2/106 |
| Acute myocardial infarctionCardiac disorders | 1/105 | 0/105 | 0/106 |
| Cardiac failureCardiac disorders | 0/105 | 1/105 | 0/106 |
| Inguinal herniaGastrointestinal disorders | 1/105 | 0/105 | 0/106 |
| Influenza like illnessGeneral disorders | 0/105 | 1/105 | 0/106 |
| Radius fractureInjury, poisoning and procedural complications | 1/105 | 0/105 | 0/106 |
| Ulna fractureInjury, poisoning and procedural complications | 1/105 | 0/105 | 0/106 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/105 | 1/105 | 1/106 |
| Ligament disorderMusculoskeletal and connective tissue disorders | 1/105 | 0/105 | 0/106 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/105 | 1/105 | 0/106 |
| Event | Part 1: Placebo | Part 1: RO7046015 Low Dose | Part 1: RO7046015 High Dose |
|---|---|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 17/105 | 20/105 | 35/106 |
| NasopharyngitisInfections and infestations | 15/105 | 20/105 | 13/106 |
| HeadacheNervous system disorders | 10/105 | 10/105 | 12/106 |
| Back painMusculoskeletal and connective tissue disorders | 8/105 | 8/105 | 11/106 |
| ConstipationGastrointestinal disorders | 6/105 | 8/105 | 10/106 |
| FallInjury, poisoning and procedural complications | 5/105 | 5/105 | 10/106 |
| NauseaGastrointestinal disorders | 9/105 | 5/105 | 9/106 |
| Upper respiratory tract infectionInfections and infestations | 9/105 | 4/105 | 9/106 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/105 | 7/105 | 4/106 |
| InsomniaPsychiatric disorders | 5/105 | 3/105 | 8/106 |
The modified intent-to-treat (mITT) population includes all participants randomized in the study who received any amount of study drug treatment.
| Age, Continuous(Years) | Part 1: Placebo | Part 1: RO7046015 Low Dose | Part 1: RO7046015 High Dose | Total |
|---|---|---|---|---|
| Mean | 59.9 ± 8.7 | 60.3 ± 8.8 | 59.4 ± 9.8 | 59.9 ± 9.1 |
| Sex: Female, Male(Participants) | Part 1: Placebo | Part 1: RO7046015 Low Dose | Part 1: RO7046015 High Dose | Total |
|---|---|---|---|---|
| Female | 34 | 34 | 35 | 103 |
| Male | 71 | 71 | 71 | 213 |
| Race/Ethnicity, Customized(Participants) | Part 1: Placebo | Part 1: RO7046015 Low Dose | Part 1: RO7046015 High Dose | Total |
|---|---|---|---|---|
| Asian | 1 | 0 | 0 | 1 |
| Black or African American | 0 | 2 | 0 | 2 |
| White | 91 | 83 | 89 | 263 |
| Unknown | 13 | 20 | 17 | 50 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Jun 2017 to primary completion in Nov 2019, 29 months.
Results were first posted in Feb 2021, 1 year 2 months after primary completion.
Of 96 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's 29 months is above that.
Counting every sponsor, half of 201 studies reached it within 28 months; a quarter within 16 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Prasinezumab